Haemonetics (NYSE:HAE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $88.00 price target on the stock.
Haemonetics (NYSE:HAE) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Haemonetics Is Still Undervalued, Even After The Rally [Seeking Alpha]
Haemonetics (NYSE:HAE) had its price target raised by analysts at Barrington Research from $86.00 to $90.00. They now have an "outperform" rating on the stock.
Haemonetics (NYSE:HAE) had its price target raised by analysts at Needham & Company LLC from $68.00 to $78.00. They now have a "buy" rating on the stock.